Overview of the FDA's Drug-Recall Process

被引：0

|

作者：

Terrie, Yvette C.

机构：

来源：

US PHARMACIST | 2019年 / 44卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：28 / 31

页数：4

相关论文

共 50 条

[1] WANTED - TIMELY RECEIPT OF DRUG-RECALL INFORMATION
HICKS, WE
CANTREL, SA
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1995, 52 (09) : 1011 - 1012
[2] Overview of FDA Drug Approval and Labeling
Clarridge, Katherine E.
Chin, Stacy J.
Stone, Kelly D.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (12): : 3051 - 3056
[3] THE FDA DRUG REVIEW PROCESS
LIPMAN, AG
[J]. HOSPITAL FORMULARY, 1988, 23 (03): : 211 - 211
[4] FDA AND DRUG APPROVAL PROCESS
KENNEDY, D
[J]. CONNECTICUT MEDICINE, 1978, 42 (10) : 651 - 656
[5] DRUG APPROVAL PROCESS AND FDA
SCHMIDT, AM
[J]. NEW YORK STATE JOURNAL OF MEDICINE, 1976, 76 (12) : 2039 - 2042
[6] The effects of lobbying on the FDA’s recall classification
Yifan Zhou
[J]. BMC Medical Ethics, 24
[7] The effects of lobbying on the FDA's recall classification
Zhou, Yifan
[J]. BMC MEDICAL ETHICS, 2023, 24 (01)
[8] FDA history, drug inspection and compliance overview
Higgins, Brooke
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
[9] A pharmacogeneticist's look at drug effects and the drug development process: an overview
Kalow, W
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (08) : 1299 - 1303
[10] FDA TO REVISE DRUG REVIEW PROCESS
WELSH, JS
[J]. AMERICAN PHARMACY, 1980, 20 (01): : 45 - 45

← 1 2 3 4 5 →